文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌局灶剂量提升治疗计划的知识库评估

Knowledge-Based Assessment of Focal Dose Escalation Treatment Plans in Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-07-03

基于FLAME随机试验539例患者数据,开发解剖学预测模型评估前列腺癌局灶剂量提升计划的肿瘤剂量是否次优,并对21例计划重新规划验证。剂量提升臂中位肿瘤D98%为84.7 Gy,重新规划后中位D98%增加3.0 Gy,预测增幅与实际增幅强相关(ρ=0.86)。

要点

  • 剂量提升臂中位肿瘤D50%和D98%分别为93.0和84.7 Gy。
  • 99%的肿瘤剂量提升超过82.4 Gy(77 Gy的107%)。
  • 预测模型可识别可规划更高提升剂量的肿瘤,ρ=0.86。

核心结论

  • 前列腺癌局灶剂量提升可行,99%的肿瘤实现了剂量提升。
  • 重新规划可增加肿瘤剂量,且与预测模型强相关,模型有潜力作为质量评估工具。

研究设计与样本

  • 基于FLAME随机试验中4家机构539例患者的计划剂量分布推导剂量体积参数。
  • 在剂量提升臂中确定重叠体积直方图并提取代表患者解剖的特征。
  • 用解剖特征线性回归预测肿瘤D98%,并对21例计划重新规划。

主要发现

  • 剂量提升臂中位肿瘤D50%和D98%分别为93.0和84.7 Gy。
  • 99%的肿瘤剂量提升大于82.4 Gy(77 Gy的107%)。
  • 两个臂均满足危及器官约束。
  • 73个解剖特征中5个可预测肿瘤D98%。
  • 预测肿瘤D98%中位数比计划D98%高4.4 Gy;重新规划后中位肿瘤D98%增加3.0 Gy;预测增幅与实际增幅强相关(ρ=0.86)。

关键数值与推荐

  • 剂量提升臂处方:肿瘤最高95 Gy,整个前列腺77 Gy(两臂相同)。
  • 剂量提升臂中位肿瘤D50%为93.0 Gy,D98%为84.7 Gy。
  • 99%的肿瘤剂量提升大于82.4 Gy(即77 Gy的107%)。
  • 预测肿瘤D98%中位数比计划高4.4 Gy;重新规划后中位D98%增加3.0 Gy;预测与实现增幅相关系数ρ=0.86。

临床怎么用

  • 危及器官约束优先于剂量提升,计划可能次优。
  • anatomy-based预测模型可用于识别可规划更高肿瘤提升剂量的计划。
  • 对预测模型提示次优的计划可考虑重新规划以增加肿瘤剂量。

局限性

  • 重新规划验证仅基于21例计划。
  • 预测模型基于4家机构的539例FLAME试验患者数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In a randomized focal dose escalation radiation therapy trial for prostate cancer (FLAME), up to 95 Gy was prescribed to the tumor in the dose-escalated arm, with 77 Gy to the entire prostate in both arms. As dose constraints to organs at risk had priority over dose escalation and suboptimal planning could occur, we investigated how well the dose to the tumor was boosted. We developed an anatomy-based prediction model to identify plans with suboptimal tumor dose and performed replanning to validate our model. METHODS AND MATERIALS: We derived dose-volume parameters from planned dose distributions of 539 FLAME trial patients in 4 institutions and compared them between both arms. In the dose-escalated arm, we determined overlap volume histograms and derived features representing patient anatomy. We predicted tumor D98% with a linear regression on anatomic features and performed replanning on 21 plans. RESULTS: In the dose-escalated arm, the median tumor D50% and D98% were 93.0 and 84.7 Gy, and 99% of the tumors had a dose escalation greater than 82.4 Gy (107% of 77 Gy). In both arms organs at risk constraints were met. Five out of 73 anatomic features were found to be predictive for tumor D98%. Median predicted tumor D98% was 4.4 Gy higher than planned D98%. Upon replanning, median tumor D98% increased by 3.0 Gy. A strong correlation between predicted increase in D98% and realized increase upon replanning was found (ρ = 0.86). CONCLUSIONS: Focal dose escalation in prostate cancer was feasible with a dose escalation to 99% of the tumors. Replanning resulted in an increased tumor dose that correlated well with the prediction model. The model was able to identify tumors on which a higher boost dose could be planned. The model has potential as a quality assessment tool in focal dose escalated treatment plans.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. van Schie MA, Janssen TM, Eekhout D, et al. Knowledge-Based Assessment of Focal Dose Escalation Treatment Plans in Prostate Cancer. Int J Radiat Oncol Biol Phys. 2020. PMID: 32629078. doi:10.1016/j.ijrobp.2020.06.072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。